Deciphera Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Total revenues
Cost and operating expenses:
Cost of sales
Research and development
Total operating expenses
Selling, general, and administrative
Total cost and operating expenses

Loss from operations
Other income (expense):
Interest and other income, net
Interest expense
Total other income (expense), net
Loss before income tax expense
Income tax expense
Net loss
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities
Currency translation adjustment
Total other comprehensive income (loss)
Total comprehensive loss
Net loss per share - basic (in dollars per share)
Net loss per share - diluted (in dollars per share)
Weighted average common shares outstanding - basic (in shares)
Weighted average common shares outstanding - diluted (in shares)

Comments